|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Ideaya Biosciences, Inc. (IDYA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
72,130,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile IDEAYA Biosciences is a synthetic lethality-focused precision medicine oncology company engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Co.'s primary synthetic lethality product candidate is IDE397, a clinical-stage methionine adenosyltransferase 2a inhibitor for patients with solid tumors having methylthioadenosine phosphorylase deletions. Co. is enrolling patients into a Phase 1 clinical trial designated as IDE397-001 to evaluate IDE397. Co. is targeting poly (ADP-ribose) glycohydrolase for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
268,000 |
311,470 |
311,470 |
Total Sell Value |
$0 |
$10,832,803 |
$11,979,134 |
$11,979,134 |
Total People Sold |
0 |
3 |
4 |
4 |
Total Sell Transactions |
0 |
11 |
26 |
26 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lackner Mark |
SVP, Head of Biology |
|
2021-02-09 |
4 |
AS |
$21.05 |
$23,234 |
D/D |
(1,104) |
0 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2021-02-09 |
4 |
OE |
$6.98 |
$7,706 |
D/D |
1,104 |
1,104 |
|
- |
|
Dillon Michael P. |
SVP, Chief Scientific Officer |
|
2021-02-09 |
4 |
AS |
$20.74 |
$103,697 |
D/D |
(5,000) |
98,789 |
|
- |
|
Dillon Michael P. |
SVP, Chief Scientific Officer |
|
2021-02-09 |
4 |
OE |
$6.92 |
$34,600 |
D/D |
5,000 |
103,789 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2021-02-08 |
4 |
AS |
$21.00 |
$6,302 |
D/D |
(300) |
0 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2021-02-08 |
4 |
OE |
$6.98 |
$2,094 |
D/D |
300 |
300 |
|
- |
|
Lampert Mark N |
See Explanation of Responses |
|
2021-02-02 |
4 |
S |
$18.00 |
$835,362 |
D/D |
(46,409) |
233,150 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2021-01-26 |
4 |
AS |
$18.30 |
$46,158 |
D/D |
(2,501) |
0 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2021-01-26 |
4 |
OE |
$4.62 |
$9,580 |
D/D |
1,500 |
2,501 |
|
- |
|
Hata Yujiro S |
President and CEO |
|
2020-12-22 |
4 |
OE |
$4.31 |
$34,480 |
D/D |
8,000 |
666,286 |
|
- |
|
Dillon Michael P. |
SVP, Chief Scientific Officer |
|
2020-12-18 |
4 |
OE |
$4.31 |
$33,403 |
D/D |
7,750 |
98,789 |
|
- |
|
Stone Paul A. |
SVP, Chief Financial Officer |
|
2020-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
444 |
15,444 |
|
- |
|
Throne Jason |
SVP, General Counsel |
|
2020-12-04 |
4 |
AS |
$14.66 |
$30,410 |
D/D |
(1,979) |
0 |
|
- |
|
Rocklage Scott M |
Former 10% holder |
|
2020-11-11 |
4 |
S |
$13.66 |
$10,928,000 |
I/I |
(800,000) |
384,496 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2020-06-30 |
4 |
B |
$13.32 |
$33,704 |
D/D |
2,531 |
237,475 |
2.37 |
- |
|
Lampert Mark N |
10% Owner |
|
2020-06-22 |
4 |
B |
$13.93 |
$274,960 |
D/D |
19,732 |
237,394 |
2.45 |
- |
|
Lampert Mark N |
10% Owner |
|
2020-06-19 |
4 |
B |
$14.39 |
$1,413,970 |
D/D |
98,264 |
236,040 |
2.45 |
- |
|
Lampert Mark N |
10% Owner |
|
2020-06-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,989,349 |
|
- |
|
Stone Paul A. |
Chief Financial Officer |
|
2020-06-17 |
4 |
AS |
$17.50 |
$55,717 |
D/D |
(3,100) |
15,000 |
|
- |
|
Stone Paul A. |
Chief Financial Officer |
|
2020-06-17 |
4 |
OE |
$4.62 |
$14,322 |
D/D |
3,100 |
18,100 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2020-06-17 |
4 |
AS |
$19.91 |
$7,428 |
D/D |
(373) |
0 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2020-06-17 |
4 |
OE |
$4.62 |
$1,723 |
D/D |
373 |
373 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2020-06-16 |
4 |
AS |
$14.93 |
$100,761 |
D/D |
(6,750) |
0 |
|
- |
|
Lackner Mark |
SVP, Head of Biology |
|
2020-06-16 |
4 |
OE |
$4.62 |
$37,942 |
D/D |
6,750 |
6,750 |
|
- |
|
Throne Jason |
VP, General Counsel |
|
2020-06-04 |
4 |
AS |
$8.66 |
$19,087 |
D/D |
(2,205) |
0 |
|
- |
|
129 Records found
|
|
Page 4 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|